Amyloid Beta and Cardiovascular Disease Intriguing Questions Indeed∗ by Williams, Bryan
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 9 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 1 . 0 1 3EDITORIAL COMMENTAmyloid Beta and Cardiovascular Disease
Intriguing Questions Indeed*Bryan Williams, MDC ardiovascular disease (CVD) and Alzheimerdisease (AD) are 2 major causes of morbidityand mortality and represent formidable
medical and societal challenges. The classical patho-
logical signature of AD is the deposition of amyloid-
rich plaques in the brain. Amyloid-beta (Abeta) is a
key constituent of these plaques, and its deposition
in the brain has been strongly implicated in the path-
ogenesis of AD. Likewise, Abeta deposition in the
wall of cerebral microvessels is pathognomonic of ce-
rebral amyloid angiopathy. To date, research into the
potential role of Abeta proteins in the pathogenesis
of disease has focused almost exclusively on the brain
and its associated vasculature. This is despite the fact
that substantial amounts of Abeta proteins are pro-
duced in the peripheral circulation and are present
in platelets, as well as atherosclerotic plaques (1).
This raises the question as to the role, if any, of Abeta
proteins in the pathogenesis of CVD.SEE PAGE 904In this issue of the Journal, Stamatelopoulos et al.
(2) reported intriguing data from retrospective cohort
studies, showing that circulating levels of Abeta40
were predictive of cardiovascular mortality in pa-
tients with established coronary heart disease (CHD)
and were predictive of the progression of vascular
disease (2). Moreover, these associations appeared
robust after adjustment for potential confounding
inﬂuences on both Abeta40 levels and cardiovascular
risk, such as age and renal function, and had*Editorials published in the Journal of the American College of Cardiology
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views of JACC or the American College of Cardiology.
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mortality over and above that obtained from the
assessment of conventional cardiovascular risk fac-
tors alone. They concluded that circulating levels of
Abeta40 may help predict which patients with
established CHD are at higher risk of cardiovascular
mortality and thus may beneﬁt from more intensive
conventional CVD risk reduction strategies. They also
suggested that these ﬁndings may point to novel
pathways for CVD development that involve Abeta40,
which may point to a novel target for CVD prevention.
Although their study is preliminary and too small
to be considered deﬁnitive, their hypothesis is
certainly worth closer attention. That said, it should
be acknowledged that the association between cir-
culating Abeta40 and mortality in patients with CHD
could simply reﬂect imperfect correction for factors
that elevate Abeta40 levels, such as impaired renal
function, which is itself a potent risk factor for car-
diovascular morbidity and mortality. In other words,
the mortality associations with Abeta40 levels could
simply be indicative of another factor that is inﬂu-
encing both cardiovascular risk and Abeta40 and
that Abeta40 is not directly contributing to the CVD
risk per se. An alternative view is that they have
identiﬁed a heretofore unrecognized causal link be-
tween Abeta40 and the pathogenesis of CVD that
would represent an important ﬁnding.
The biology of Abeta proteins is complex, and the
normal physiological functions of Abeta proteins are
poorly understood. It is notable, however, that Abeta
proteins are highly conserved between species, sug-
gesting an important function. It has been proposed
that Abeta proteins, in both normal and pathological
settings, play a role in modulating inﬂammatory re-
sponses and may have a role in natural antimicrobial
defenses (3,4).
Abeta proteins are generated from the amyloid pro-
tein precursor (APP), a trans-membrane glycoprotein
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secretases to release Abeta proteins. These Abeta
proteins are hydrophobic monomers, consisting of 39
to 42 amino acids, the most common of which are
Abeta40 and Abeta42 (5). Abeta proteins circulate in
the plasma and cerebrospinal ﬂuid, Abeta40 being
the most abundant. The longer form, Abeta42, is most
abundant in the classic cerebral plaques of AD,
whereas Abeta40 is the more abundant form in the
vascular wall and in platelets. The dynamics and
regulation of Abeta protein production and degrada-
tion/clearance are also poorly understood. Platelets
are thought to be the major source of circulating Abeta
proteins. Platelets contain both APP and Abeta40
in their alpha-granules and represent >90% of circu-
lating APP and Abeta (6). The production of Abeta
proteins is inﬂuenced by cholesterol levels and in
particular the cholesterol content of cell membranes.
In cell culture, increased cholesterol levels promote
the production of Abeta proteins from APP, whereas
decreased cholesterol levels decrease the production
of Abeta (5). Statins have also been shown to reduce
Abeta protein production in cultured cells by pro-
moting a favorable shift in APP processing away
from Abeta production, associated with decreased
beta- and gamma-secretase–mediated APP proteoly-
sis. The circulating level of Abeta proteins is
also inﬂuenced by their clearance, and they are
actively degraded by a range of proteases, including
endothelin-converting enzyme, insulin-degrading
enzyme, plasmin, angiotensin-converting enzyme,
and especially neprilysin. This latter protease is
notable because of the emergence of neprilysin in-
hibitors as a therapeutic option for heart failure.
Finally, Abeta clearance also follows a circadian
rhythm, with the greatest clearance of Abeta occurring
during sleep, suggesting that plasma levels will be
inversely related to sleep duration.
Beyond the circulation, Abeta proteins (predomi-
nantly Abeta40) have been identiﬁed in human
atherosclerotic lesions, as well as activated and
nonactivated human platelets. In a study of human
atherosclerotic plaques from the aortas of elderly
people, Abeta40 was 100 times more abundant that
Abeta42 (1). The predominant source of Abeta40 in
atherosclerotic plaques is thought to derive from the
alpha-granules of platelets and/or processing of APP
in the vascular wall, notably by endothelial cells or
the myocytes of the arterial media. Thus, human
atherosclerotic plaques in the peripheral circulation
often contain APP, Abeta40, platelets, and activated
macrophages (7). Macrophage activation within the
atherosclerotic plaque seems to be mediated by pro-
cessing of platelet-derived APP to Abeta by secretaseenzymes within the macrophage (8). Activation of
platelets within the plaque also leads to Abeta
release. This latter ﬁnding is intriguing because the
predominant Abeta protein in the platelet and the
circulation is Abeta40 and the study of Stamatelo-
poulos et al. (2) reported an association between
circulating Abeta40 levels and cardiovascular mor-
tality in patients with an established atherosclerotic
plaque burden (2). Could it be that circulating levels
of Abeta40 are at least in part a marker of athero-
sclerotic plaque burden and/or macrophage activa-
tion within the plaque? Is Abeta40 a biomarker of
plaque burden or vulnerability?
There are a number of mechanisms whereby the
presence of Abeta proteins in the vascular wall in
general, or more speciﬁcally the atherosclerotic pla-
que, could contribute to the genesis and evolution of
CVD. Cerebral amyloid angiopathy is a good example
whereby the deposition of Abeta proteins in the
vascular wall of cerebral vessels creates a chronic
inﬂammatory microenvironment, leading to a loss of
vascular wall integrity and a propensity to micro-
bleeds and hemorrhage. Prior studies have suggested
that exposing human endothelial cells to Abeta40
in vitro induces CD40 expression and interleukin 1-
beta and interferon-gamma secretion (9). Although
exposing human vascular smooth muscle cells
(VSMCs) to Abeta40 did not directly promote an in-
ﬂammatory response, it did lead to a dedifferentia-
tion of VSMCs from a contractile to a proinﬂammatory
secretory phenotype and preactivated VSMCs to
generate an ampliﬁed inﬂammatory response to cy-
tokines (e.g., interleukin 1-beta via pathways thought
to involve phosphoinositide 3-kinase and possibly
nuclear factor kappaB) (10). Thus, it is possible to
envision Abeta40 activation of the endothelial cell
and VSMC acting in concert to initiate and amplify an
inﬂammatory response. It is also conceivable that this
mechanism could prime the plaque for an enhanced
inﬂammatory response to infectious agents or other
stresses, linking acute infection or stress to acute
CVD events. Furthermore, Abeta40 has been shown
to induce apoptosis of VSMCs and activate matrix
metalloproteinase-2 and possibly matrix metal-
loproteinase-9, all of which could contribute to
increased plaque instability (11). Inﬂammation may
also be induced by Abeta binding to the receptor
for advanced glycation end products, which activates
the Janus kinase/signal transducer and activator of
transcription pathway and nuclear factor kappaB
signaling (12).
Finally, it is unlikely that Abeta proteins have been
preserved through evolution to induce cell injury and
more likely that their proinﬂammatory action is a
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maladaptive. In this regard, there is an emerging view
that the normal function of Abeta proteins is as an
antimicrobial peptide (AMP) (4). AMPs are a naturally
occurring family of peptides with potent, broad-
spectrum antibiotic activity that targets Gram-
negative and Gram-positive bacteria, mycobacteria,
enveloped viruses, fungi, and protozoa, which play a
key role in innate immunity. AMPs are also potent
immunomodulators that mediate cytokine release
and adaptive immune responses (13). The physi-
ochemical and biological properties of Abeta proteins
are remarkably similar to those of other members of
the AMP family of peptides. Only 1 AMP has been
identiﬁed in humans, the LL-37 peptide (14), which
shows remarkable similarity to Abeta in its propensity
to form cytotoxic soluble oligomers. Patients with low
levels of LL-37 are at increased risk for serious in-
fections (15), and genetically modiﬁed mice that lack
endogenous rodent Abeta appear to have increased
susceptibility to pathogens (16). Conversely, high
levels of LL-37 in patients are associated with
the pathology of several presumed noninfectious
diseases, which remarkably includes plaques inatherosclerosis (17). A recent study showed that Abeta
possesses potent antimicrobial activity against at
least 8 clinically important bacteria and may thus
function in vivo as an AMP and play a role as
an effector molecule of innate immunity (4). It is
possible that this process becomes maladaptive in
response to chronic subclinical infection, raising the
specter once again of an infectious etiology for
vascular dysfunction, atheroma, and plaque rupture.
In conclusion, the study of Stamatelopoulos et al.
(2) highlights a potential link between Abeta and CVD
mortality (2). It is an observation that requires repli-
cation but stimulates debate about the normal func-
tion of Abeta and its role, if any, in vascular disease.
Is it a biomarker or mediator of chronic subclinical
vascular inﬂammation and/or a poorly studied natural
AMP defense against a hitherto unidentiﬁed chronic
infectious agent implicated in the development of
atheromatous disease? Intriguing questions indeed.
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